Thyroid Fellow, Women's College Hospital and University of Toronto, Division of Endocrinology & Metabolism, Department of Medicine, Toronto, Ontario, Canada.
The VA Outcomes Group, US Department of Veterans Affairs Medical Center, White River Junction, Vermont.
Curr Opin Endocrinol Diabetes Obes. 2022 Oct 1;29(5):492-496. doi: 10.1097/MED.0000000000000756. Epub 2022 Jul 18.
Our aim is to discuss the concepts of sex and gender in the context of thyroid cancer epidemiology.
It has been long-established in global epidemiologic data that thyroid cancer incidence rates are higher in women than men. However, what has been less well understood is whether this reflects sex disparities in cancer susceptibility, gender disparities in detection, or a combination. A recent meta-analysis of autopsy data from individuals who were not known to have thyroid cancer in their lifetime demonstrated no difference in the prevalence of thyroid cancer in women and men, suggesting that gender differences may be the reason for gender-based differences in thyroid cancer detection. This finding, and sex differences in auto immunity and other factors that may affect cancer susceptibility are explored.
Additional research to explore gender- and sex-specific data on thyroid cancer would inform our understanding of the differences and similarities between men and women in susceptibility and detection of thyroid cancer and help to optimize disease management for all genders and both sexes.
我们旨在讨论甲状腺癌流行病学中性别概念的相关问题。
全球流行病学数据长期以来表明，女性甲状腺癌发病率高于男性。然而，人们不太了解的是，这是否反映了癌症易感性方面的性别差异、检测方面的性别差异，还是两者的综合。最近对一生中未被诊断患有甲状腺癌的个体尸检数据进行的荟萃分析表明，女性和男性甲状腺癌的患病率没有差异，这表明性别差异可能是导致甲状腺癌检测中性别差异的原因。本研究还探讨了自身免疫和其他可能影响癌症易感性的因素方面的性别差异。
进一步研究甲状腺癌的性别和性别特异性数据，将有助于我们了解男性和女性在甲状腺癌易感性和检测方面的差异和相似之处，并有助于优化所有性别和男女两性的疾病管理。
